Source: Marginal REVOLUTION
The mental health startup ecosystem has built a multi-billion dollar business on the assumption that algorithmic chatbots can meaningfully substitute for human clinicians—a bet that depends entirely on clinical outcomes we still don't have at scale. New research suggesting mixed or modest efficacy challenges the narrative that AI can democratize therapy, forcing apps like Woebot and Replika to either generate harder evidence or position themselves as supplements rather than alternatives to licensed care. Venture capital will follow the data: if randomized trials consistently show weak effects, funding dries up and the market consolidates around players who can survive on lower user expectations and smaller revenue bases.